Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Graves' disease and pregnancy.

Frédéric Illouz1, Dominique Luton2, Michel Polak3

  • 1Service d'endocrinologie diabète nutrition, centre de référence des maladies rares de la thyroïde et des récepteurs hormonaux, CHU d'Angers, 49933 Angers cedex 09, France.

Annales D'Endocrinologie
|September 19, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for prevention of iodine deficiency during pregnancy and breastfeeding in France.

Annales d'endocrinologie·2026
Same author

Advancing Early-Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring.

Diabetes, obesity & metabolism·2026
Same author

Rare Causes of Pediatric Primary Adrenal Insufficiency: An Observational Cohort Study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

A histo-clinical score to predict evolution to radioactive iodine-refractory of the follicular cell-derived thyroid carcinoma (PREDIRAIR): a single-centre, prospective, cohort study.

EClinicalMedicine·2026
Same author

Validating the 2022 WHO classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance.

Histopathology·2026
Same author

Monopolar Single Tip Radiofrequency as Treatment of Giant Placental Chorioangioma.

Prenatal diagnosis·2026

Managing Graves' disease in pregnancy requires careful monitoring for rare but severe fetal, neonatal, and maternal risks. Treatment focuses on antithyroid drugs, with ongoing surveillance for both mother and child post-delivery.

Area of Science:

  • Endocrinology
  • Obstetrics
  • Neonatology

Background:

  • Graves' disease in pregnancy presents significant risks, including fetal/neonatal complications and maternal pre-eclampsia.
  • Persistent maternal anti-TSH-receptor antibodies necessitate careful management and monitoring.

Purpose of the Study:

  • To outline the specific management strategies for Graves' disease during pregnancy.
  • To highlight potential complications and monitoring protocols for mother and fetus.

Main Methods:

  • Review of management protocols for Graves' disease in pregnant patients.
  • Emphasis on multidisciplinary fetal and neonatal monitoring.
  • Surveillance for maternal hyperthyroidism recurrence post-delivery.

Main Results:

Keywords:
Fetal ultrasoundGraves’ diseaseMaladie de BasedowMultidisciplinarityMultidisciplinaritéNeonatal monitoringSurveillance néonataleTRABTeratogenicityTératogénicitéÉchographie fœtale

Related Experiment Videos

  • Antithyroid drugs are the sole treatment during pregnancy; levothyroxine is not co-administered.
  • Fetal goiter, neonatal dysthyroidism, premature birth, and pre-eclampsia are key risks.
  • Maternal and neonatal monitoring are crucial, especially with persistent antibodies or antithyroid treatment.

Conclusions:

  • Effective management of Graves' disease in pregnancy involves targeted treatment and comprehensive monitoring.
  • Long-term neurodevelopmental outcomes in children born to mothers with Graves' disease require further investigation.